Skip to main content

 Partners in Discovery

Vanderbilt-Ingram Cancer Center

Vanderbilt-Ingram Cancer Center is at the forefront of new discoveries that help us prevent, find, treat, manage and cure cancer. But we can't make these discoveries alone. Our patients, caregivers, community leaders, donors, volunteers, and educators contribute their insight, time, and passion to advancing the discoveries that lead us closer to a cure.

No matter how cancer has touched your life, you are a key partner in our efforts to save lives and improve the quality of life for those with cancer. 

Proven Track Record

A leader in research, innovation and treatment. We are one of 53 National Cancer Institute-designated Comprehensive Cancer Centers, dedicated to an integrated and patient-focused approach.

NCI badge

Patients, Partners, Progress

Our patients and families are our most important partners in discovery – and the motivation behind our efforts to advance research and improve cancer care.    

Read their stories from Momentum magazine. 

Cancer Center News

Latest news about our research, patient care programs, outreach and educational events.

Vanderbilt’s Dr. W. Kimryn Rathmell to be appointed director of the National Cancer Institute

Vanderbilt’s W. Kimryn Rathmell, MD, PhD to be appointed director of the National Cancer Institute.

Vanderbilt-Ingram Cancer Center earns NCI Merit Award

Vanderbilt-Ingram Cancer Center (VICC) has earned a Merit Extension Award from the National Cancer Institute (NCI) in recognition of more than a decade of sustained exceptional progress.

VUMC Part of Major Step to Achieving Precision Medicine

An analysis of genomic data from nearly 250,000 participants in the National Institutes of Health’s All of Us Research Program has identified more than 275 million previously unreported genetic variations, nearly 4 million of which have potential health consequences. The data, reported February 19th in the journal Nature, constitutes a research resource that is unprecedented in its scale and diversity, as 77% of the participants historically have been underrepresented in biomedical research, and 46% are from underrepresented racial and ethnic minorities